人乳头状瘤病毒相关口咽鳞状细胞癌的特点及临床分析
作者:
基金项目:

中国科学院科研仪器设备研制项目(YJKYYQ20180039);北京市医院管理局消化内科学科协同发展中心消化专项(XXZ0604)。


Characteristics and clinical analysis of human papillomavirus-related oropharyngeal squamous cell carcinoma
Author:
  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • | |
    摘要:

    目的 分析人乳头状瘤病毒(HPV)相关口咽鳞状细胞癌(OPSCC)的临床特点,探讨不同治疗方案对OPSCC患者生活质量的影响,以期更好地指导制定临床治疗方案并判断预后。方法 收集2014年1月-2019年1月在北京友谊医院诊治的38例OPSCC患者临床资料,男31例,女7例;其中扁桃体癌24例、舌根癌14例;HPV阳性患者13例,阴性患者25例;I、II期患者10例,III、IV期患者28例。38例患者中行同步放化疗4例,单纯根治性放疗2例,手术加术后放疗或放化疗27例,诱导化疗+术前放疗+手术或术后补充放疗5例。采用χ2检验分析HPV感染的临床特点,采用Kaplan-Meier法、Log-rank单因素分析和Cox回归模型多因素分析法计算生存率和预后相关因素分析;非参数秩和检验进行生活质量分析。结果 在OPSCC患者中,非吸烟、饮酒患者HPV阳性率更高(P=0.014,P=0.049),HPV相关OPSCC患者更易发生颈部淋巴结转移(P=0.032)。HPV阳性以及肿瘤分期I、II患者总生存率更高(P=0.003,P=0.006),且为影响患者预后的独立危险因素。3种治疗方案患者总生存率差异无统计学意义(P>0.05),但同步放化疗患者吞咽功能障碍更显著,差异存在统计学意义(P=0.002)。结论 HPV相关OPSCC患者中多为非吸烟、饮酒的人群,更容易发生颈部淋巴结转移,但预后相对较好。可考虑降级治疗以保护患者的吞咽功能,改善治疗后的生活质量。

    Abstract:

    Objective To analyze the clinical characteristics, survival rate and prognosis of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC), and to explore the impact of different treatment options on patients' quality of life, so as to make better treatment plan and estimate the prognosis.Methods Clinical data of 38 patients with HPV-related OPSCC diagnosed and treated in Beijing Friendship Hospital from Jan 2014 to Jan 2019 were collected. There were 31 males and 7 females. The OPSCC included tonsil cancer 24 cases, tongue base cancer 14 cases. Of them, 13 cases were HPV positive and 25 were negative. As for the clinical stage, 10 cases were stage I~II and 28 were stage III~IV. Six cases were treated with concurrent chemoradiotherapy or radiotherapy alone, 27 with surgery plus postoperative chemoradiotherapy/radiotherapy, and 5 with induction chemotherapy plus radiotherapy and surgery or postoperative supplementary radiotherapy. The clinical characteristics of HPV infection were analyzed by chi-square test. The survival rate and prognostic factors were calculated by Kaplan-Meier method, log-rank univariate analysis and Cox regression model multivariate analysis. The quality of life was analyzed by the non-parametric rank sum test.Results Among all the patients, those with neither smoking nor drinking had higher HPV positive rates (P=0.014, P=0.049), and those with positive HPV were more likely to have cervical lymph node metastasis (P=0.032). The overall survival rates of patients with positive HPV and tumor stage I-II were higher (P=0.003,P=0.006), which were independent risk factors affecting the prognosis of patients. There were no statistical differences among the overall survival rate of patients treated with the three above-mentioned treatment protocols. However, the patients with concurrent chemoradiotherapy had more significant swallowing dysfunction and the difference was statistically significant (P=0.002).Conclusions Most of the HPV positive OPSCC patients are non-smoking, non-drinking and more likely to have cervical lymph node metastasis, but the prognosis is relatively good. Therefore, treatment de-escalation should be considered to protect the swallowing function and improve the quality of life after treatment.

    网友评论
    网友评论
    分享到微博
    发 布
    参考文献
    [1] Giraldi L, Leoncini E, Pastorino R et al. Alcohol and cigarette consumption predict mortality in patients with head and neck cancer:a pooled analysis within the International Head and Neck Cancer Epidemiology (INHANCE) Consortium[J]. Ann Oncol, 2017, 28(11):2843-2851.
    [2] Marziliano A, Teckie S, Diefenbach MA. Alcohol-related head and neck cancer:Summary of the literature[J].Head Neck, 2020, 42(4):732-738.
    [3] Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer[J]. N Engl J Med, 2003, 348(6):518-527.
    [4] Mehanna H, Beech T, Nicholson T, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region[J]. Head Neck,2013,35(5):747-755.
    [5] Lewis JS, Beadle B, Bishop JA, et al. Human papillomavirus testing in head and neck carcinomas:Guideline from the College of American Pathologists[J]. Arch Pathol Lab Med, 2018, 142(5):559-597.
    [6] Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual[M]. 8th ed. New York:Springer, 2017:120, 128-130.
    [7] Asthana S, Labani S, Kailash U, et al. Association of smokeless tobacco use and oral cancer:A systematic global review and meta-analysis[J]. Nicotine Tob Res, 2019,21(9):1162-1171.
    [8] Mehrtash H, Duncan K, Parascandola M, et al. Defining a global research and policy agenda for betel quid and areca nut[J]. Lancet Oncology, 2017, 18(12):e767-e775.
    [9] Khalid MB, Ting P, Pai A, et al. Initial presentation of human papillomavirus-related head and neck cancer:A retrospective review[J]. Laryngoscope, 2019, 129(4):877-882.
    [10] Taberna M, Mena M, Pavón MA, et al. Human papillomavirus-related oropharyngeal cancer[J].Ann Oncol, 2017, 28(10):2386-2398.
    [11] Hermida-Prado F, Menéndez ST, Albornoz-Afanasiev P, et al. Distinctive expression and amplification of genes at 11q13 in relation to HPV status with impact on survival in head and neck cancer patients[J]. J Clin Med, 2018, 7(12):501.
    [12] Klussmann JP, Mooren JJ, Lehnen M, et al. Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications[J]. Clin Cancer Res, 2009,15(5):1779-1786.
    [13] Scheffner M, Huibregtse JM, Vierstra RD, et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53[J]. Cell,1993,75(3):495-505.
    [14] Chai RC, Lambie D, Verma M, et al. Current trends in the etiology and diagnosis of HPV-related head and neck cancers[J]. Cancer Med, 2015, 4(4):596-607.
    [15] Wright MF, Weiss VL, Lewis JS Jr, et al. Determination of high-risk HPV status of head and neck squamous cell carcinoma using the Roche cobas HPV test on cytologic specimens and acellular supernatant fluid[J].Cancer Cytopathol, 2020, 128(7):482-490.
    [16] Prigge ES, Arbyn M, von Knebel Doeberitz M, et al. Diagnostic accuracy of P16(ink4a) immunohistochemistry in oropharyngeal squarnous cell carcinomas:A systematic review and meta-analysis[J]. Int J Cancer,2017,140(5):1186-1198.
    [17] Devaraja K, Aggarwal S, Verma SS et al. Clinico-pathological peculiarities of human papilloma virus driven head and neck squamous cell carcinoma:A comprehensive update[J]. Life Sci, 2020, 245:117383.
    [18] Mehanna H, Beech T, Nicholson T, et al:Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region[J]. Head Neck,2013,35(5):747-755.
    [19] Qureishi A, Mawby T, Fraser L,et al:Current and future techniques for human papilloma virus (HPV) testing in oropharyngeal squamous cell carcinoma[J]. Eur Arch Otorhinolaryngol,2017, 274(7):2675-2683.
    [20] 张永侠,张彬,高黎, 等.口咽鳞状细胞癌318例临床分析[J].中华耳鼻咽喉头颈外科杂志,2013,48(5):398-404.
    [21] Wang H, Wang B, Wei J, et al. Molecular mechanisms underlying increased radiosensitivity in human papillomavirus-associated oropharyngeal squamous cell carcinoma[J]. Int J Biol Sci, 2020, 16(6):1035-1043.
    [22] Nichols AC, Theurer J, Prisman E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR):an open-label, phase 2, randomised trial[J]. Lancet Oncol, 2019, 20(12):1349-1359.
    [23] Dabas S, Gupta K, Sharma AK, et al. Oncological outcome following initiation of treatment for stage III and IV HPV negative oropharyngeal cancers with transoral robotic surgery (TORS)[J]. Eur J Surg Oncol, 2019, 45(11):2137-2142.
    [24] Golusiński W, Golusińska-Kardach E. Current role of surgery in the management of oropharyngeal cancer[J]. Front Oncol, 2019, 9:388.
    [25] Fakhry C, Zhang Q, Gillison ML, et al. Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer:Implications for risk-based therapeutic intensity trials[J]. Cancer, 2019, 125(12):2027-2038.
    [26] 许德斌,陈文宽,郭朱明, 等.口咽鳞状细胞癌患者治疗及预后因素分析[J].中国耳鼻咽喉头颈外科,2011,18(6):284-287.
    [27] Hargreaves S, Beasley M, Hurt C, et al. Deintensification of adjuvant treatment after transoral surgery in patients with human papillomavirus-positive oropharyngeal cancer:The conception of the PATHOS study and its development[J]. Front Oncol, 2019, 9:936.
    [28] Karsten RT, van den Brekel MWM, Smeele LE, et al. Patient-reported swallowing function after treatment for early-stage oropharyngeal carcinoma:Population-based study[J].Head Neck, 2020,42(8):1981-1993.
    [29] Gau M, Karabajakian A, Reverdy T, et al. Induction chemotherapy in head and neck cancers:Results and controversies[J].Oral Oncol, 2019, 95:164-169.
    引证文献
引用本文

袁硕卿,张奥博,董研博,王振晓,刘良发.人乳头状瘤病毒相关口咽鳞状细胞癌的特点及临床分析[J].中国耳鼻咽喉颅底外科杂志,2021,27(6):691-697

复制
分享
文章指标
  • 点击次数:568
  • 下载次数: 354
历史
  • 收稿日期:2021-01-01
  • 在线发布日期: 2022-01-06
温馨提示

本刊唯一投稿网址:www.xyosbs.com
唯一办公邮箱:xyent@126.com
编辑部联系电话:0731-84327210,84327469
本刊从未委托任何单位、个人及其他网站代理征稿及办理其他业务联系,谨防上当受骗!

关闭